August 17, 2017

Context Therapeutics, a biotechnology company dedicated to creating new medicines for cancer, fibrosis, and neurodegenerative disease, today announced that the company has entered into agreements with three research partners. The company will collaborate with experts in the field of Sigma1 protein and its role in disease biology at the Cedars-Sinai Medical Center, Fred Hutchinson Cancer Research Center, and Synergie Lyon Cancer. Context will work with investigators at these institutions to determine the role of Sigma1 in certain animal disease models and to evaluate the activity of its proprietary Sigma1 inhibitors in biopsy explant models, animal models, and human cellular systems.

Read Full Article